Prelude Therap 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
P-500 / Pathos
NCT04089449: A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas

Hourglass Nov 2021 - Nov 2021 : From trial for glioblastoma and CNS lymphoma at SNO 2021
Checkmark Interim data from trial for solid tumors, CNS lymphoma and gliomas
Mar 2021 - Mar 2021: Interim data from trial for solid tumors, CNS lymphoma and gliomas
Completed
1
86
US
PRT811
Prelude Therapeutics
Advanced Solid Tumor, Recurrent Glioma
03/23
03/23
PRT2527 / Prelude Therap
NCT05159518: A Study of PRT2527 in Participants With Advanced Solid Tumors

Completed
1
30
US
PRT2527
Prelude Therapeutics
Sarcoma, Castrate Resistant Prostate Cancer, Hormone Receptor Positive HER2 Negative Breast Cancer, Non-small Cell Lung Cancer, Solid Tumors With Known MYC Amplification
12/23
12/23
PRT2527-02, NCT05665530: A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

Active, not recruiting
1
86
Europe, Canada, US, RoW
PRT2527, Zanubrutinib, Venetoclax
Prelude Therapeutics, BeiGene
Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Mantle Cell Lymphoma (MCL), Richter's Syndrome, T-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Marginal Zone Lymphoma, Myeloid Malignancies, Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndrome (MDS), MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome
11/25
03/26
PRT1419 IV / Prelude Therap
NCT04837677: A Study of PRT1419 in Patients With Advanced Solid Tumors

Completed
1
26
US
PRT1419
Prelude Therapeutics
Sarcoma, Melanoma, Lung Cancer, Breast Cancer, Esophageal Cancer, Cervical Cancer, Head and Neck Cancer
02/23
02/23
NCT05107856: PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies

Terminated
1
21
US
PRT1419, Azacitidine, Venetoclax
Prelude Therapeutics
Acute Myeloid Leukemia, B-cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelomonocytic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Small Lymphocytic Lymphoma
01/24
01/24
PRT3645 / Prelude Therap
NCT05538572: A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors

Completed
1
22
US, RoW
PRT3645
Prelude Therapeutics
Breast Cancer, Glioblastoma, Head and Neck Squamous Cell Carcinoma, Malignant Mesothelioma, Non-small Cell Lung Cancers, Sarcoma, Endometrial Cancer
06/24
06/24
PRT3789 / Prelude Therap
KEYNOTE-G02, NCT06682806: A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

Recruiting
2
60
Europe, US
PRT3789, pembrolizumab, KEYTRUDA®
Prelude Therapeutics, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Esophageal Cancer, Metastatic Solid Tumor, Non-small Cell Lung Cancers, SMARCA4 Gene Mutation
08/27
12/27
PRT3789-01, NCT05639751: PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation

Active, not recruiting
1
135
Europe, US, RoW
PRT3789, Docetaxel
Prelude Therapeutics
Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Cancers, SMARCA4 Gene Mutation
03/26
03/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
P-500 / Pathos
NCT04089449: A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas

Hourglass Nov 2021 - Nov 2021 : From trial for glioblastoma and CNS lymphoma at SNO 2021
Checkmark Interim data from trial for solid tumors, CNS lymphoma and gliomas
Mar 2021 - Mar 2021: Interim data from trial for solid tumors, CNS lymphoma and gliomas
Completed
1
86
US
PRT811
Prelude Therapeutics
Advanced Solid Tumor, Recurrent Glioma
03/23
03/23
PRT2527 / Prelude Therap
NCT05159518: A Study of PRT2527 in Participants With Advanced Solid Tumors

Completed
1
30
US
PRT2527
Prelude Therapeutics
Sarcoma, Castrate Resistant Prostate Cancer, Hormone Receptor Positive HER2 Negative Breast Cancer, Non-small Cell Lung Cancer, Solid Tumors With Known MYC Amplification
12/23
12/23
PRT2527-02, NCT05665530: A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

Active, not recruiting
1
86
Europe, Canada, US, RoW
PRT2527, Zanubrutinib, Venetoclax
Prelude Therapeutics, BeiGene
Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Mantle Cell Lymphoma (MCL), Richter's Syndrome, T-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Marginal Zone Lymphoma, Myeloid Malignancies, Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndrome (MDS), MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome
11/25
03/26
PRT1419 IV / Prelude Therap
NCT04837677: A Study of PRT1419 in Patients With Advanced Solid Tumors

Completed
1
26
US
PRT1419
Prelude Therapeutics
Sarcoma, Melanoma, Lung Cancer, Breast Cancer, Esophageal Cancer, Cervical Cancer, Head and Neck Cancer
02/23
02/23
NCT05107856: PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies

Terminated
1
21
US
PRT1419, Azacitidine, Venetoclax
Prelude Therapeutics
Acute Myeloid Leukemia, B-cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelomonocytic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Small Lymphocytic Lymphoma
01/24
01/24
PRT3645 / Prelude Therap
NCT05538572: A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors

Completed
1
22
US, RoW
PRT3645
Prelude Therapeutics
Breast Cancer, Glioblastoma, Head and Neck Squamous Cell Carcinoma, Malignant Mesothelioma, Non-small Cell Lung Cancers, Sarcoma, Endometrial Cancer
06/24
06/24
PRT3789 / Prelude Therap
KEYNOTE-G02, NCT06682806: A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

Recruiting
2
60
Europe, US
PRT3789, pembrolizumab, KEYTRUDA®
Prelude Therapeutics, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Esophageal Cancer, Metastatic Solid Tumor, Non-small Cell Lung Cancers, SMARCA4 Gene Mutation
08/27
12/27
PRT3789-01, NCT05639751: PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation

Active, not recruiting
1
135
Europe, US, RoW
PRT3789, Docetaxel
Prelude Therapeutics
Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Cancers, SMARCA4 Gene Mutation
03/26
03/26

Download Options